For research use only. Not for therapeutic Use.
GSK3186899 (Cat.No:I020012) is a novel small molecule inhibitor developed by GlaxoSmithKline (GSK). It targets the protein kinase B-Raf, a key component of the MAPK/ERK signaling pathway involved in cell growth and proliferation. GSK3186899 has demonstrated potential as an anti-cancer agent in preclinical studies, particularly in BRAF-mutant tumors. Clinical investigations are underway to evaluate its therapeutic efficacy.
| Catalog Number | I020012 |
| CAS Number | 1972617-87-0 |
| Molecular Formula | C₁₉H₂₈F₃N₇O₃S |
| Purity | ≥95% |
| Reference | [1]. Wyllie S, et al. Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature. 2018 Aug;560(7717):192-197. |
